Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Pulmonary Medicine

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1601565

This article is part of the Research TopicApplication of Multimodal Data and Artificial Intelligence in Pulmonary DiseasesView all 10 articles

Prognostic Impact of Angiotensin-Converting Enzyme Inhibitors and Dexmedetomidine in Acute Respiratory Distress Syndrome: A MIMIC-IV-Based Retrospective Cohort Analysis Author names

Provisionally accepted
Qingli  HongQingli Hong1Xiaozan  YangXiaozan Yang1Huahong  YangHuahong Yang1Xuanzhao  ZhouXuanzhao Zhou2Jiaqi  TangJiaqi Tang3Zhongmei  WenZhongmei Wen1*
  • 1The First Hospital of Jilin University, Changchun, China
  • 2The Central Laboratory of the First Hospital of Jilin University, Changchun, Jilin Province, China
  • 3Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

Background Acute respiratory distress syndrome (ARDS) is a prevalent condition in the respiratory department and intensive care unit that considerably influences prognosis. Prior research has demonstrated that angiotensin converting enzyme inhibitors (ACEIs) or dexmedetomidine can improve the prognosis of ARDS. Nonetheless, the combinatorial effect of ACEI and dexmedetomidine on the prognosis of ARDS remains to be investigated.Method A retrospective study was conducted on the data of 696 patients with ARDS collected from the Medical Information Mart for Intensive Care IV database. Subsequently, a Cox regression model was constructed to screen meaningful variables. Moreover, multi-model Cox regression was constructed to exclude the interference of confounding factors and explore the effects of ACEIs alone, dexmedetomidine alone, and ACEI combined with dexmedetomidine on the prognosis of patients with ARDS. Finally, it was verified by plotting the Kaplan-Meier survival curve.

Keywords: Dexmedetomidine, ARDS, mimic iv, prognosis, Clinical decision

Received: 28 Mar 2025; Accepted: 04 Aug 2025.

Copyright: © 2025 Hong, Yang, Yang, Zhou, Tang and Wen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Zhongmei Wen, The First Hospital of Jilin University, Changchun, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.